WHO ICTRP trial
A Phase II/III Investigator Initiated Clinical Traial Evaluating the Efficacy…
JPRN-jRCT2031200360 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-jRCT2031200360 |
|---|---|
| Public title | A Phase II/III Investigator Initiated Clinical Traial Evaluating the Efficacy and Safety of Remimazolam in Japanese Patients Undergoing Gastrointestinal Endoscopy |
| Scientific title | A Phase II/III Investigator Initiated Clinical Traial Evaluating the Efficacy and Safety of Remimazolam in Japanese Patients Undergoing Gastrointestinal Endoscopy |
| Primary sponsor | Ikehara Hisatomo |
| Secondary sponsors | Mundipharma K.K |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 2-3 |
| Conditions | Japanese patients undergoing upper gastrointestinal endoscopy or colonoscopy without analgesics |
| Interventions | Dose-finding step Remimazolam is administered at the following doses Cohort 1: Initial dose 2 mg Additional dose 1 mg / dose Cohort 2: Initial dose 3 mg Additional dose 1 mg / dose Cohort 3: Initial dose 5 mg Additional dose 2 mg / dose… |
| Registration date | Feb 15, 2021 |
| Target size | 150 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: